In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series

Abstract

The new lead series were shown to have cidal pharmacodynamic activity. The absence of cross-resistance with any of the current antileishmanial drugs opens possibilities for combination treatment to reduce the likelihood of treatment failures and drug resistance.